Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

McGill University

$105,000.00

uPA: a novel actionable target for patients with lung squamous cell carcinomas.

EF 2019-20

Résumé
Lung cancer is by far the greatest cause of cancer-related death. More people die from lung cancer than breast cancer, colon cancer and prostate cancer combined. Yet funding for lung cancer remains poor. While treatment for primary lung cancer can be intermittently effective, the vast majority of patients quickly recur, ultimately leading to lung cancer-related death. Immunotherapy has shown great promise with improved outcomes and prolonged survival in a wide variety of cancers, including lung cancer. However, over 60% of lung cancer patients treated with immunotherapy will fail to respond and an even larger proportion will fail to respond to chemotherapy. Therefore, this research proposal is aimed at improving these outcomes to reduce the incidence of recurrence in lung cancer patients. We have identified a promising new therapeutic target for lung cancer. This target has been investigated in breast cancer but not in lung cancer where our preliminary data clearly indicates a much stronger indication. Interestingly, a new drug acting on this target is currently being tested in clinical trials for breast cancer. Our goal is to demonstrate using pre-clinical models that this drug is effective for treatment of lung cancer. Should our results prove to be promising, these data will set the stage for early translation to a clinical trial for lung cancer.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
416940
Name
Fiore Amanda
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
uPA: a novel actionable target for patients with lung squamous cell carcinomas.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Biomarker; Chemotherapy; Immunotherapy Adjuvant; Lung Cancer Subtyping; Non-Small Cell Lung Carcinoma; Personalized Medicine; Preclinical Lung Cancer Models; Squamous Cell Carcinoma Of The Lung; Urokinase; Urokinase-Type Plasminogen Activator
Abstract
Lung cancer is by far the greatest cause of cancer-related death. More people die from lung cancer than breast cancer, colon cancer and prostate cancer combined. Yet funding for lung cancer remains poor. While treatment for primary lung cancer can be intermittently effective, the vast majority of patients quickly recur, ultimately leading to lung cancer-related death. Immunotherapy has shown great promise with improved outcomes and prolonged survival in a wide variety of cancers, including lung cancer. However, over 60% of lung cancer patients treated with immunotherapy will fail to respond and an even larger proportion will fail to respond to chemotherapy. Therefore, this research proposal is aimed at improving these outcomes to reduce the incidence of recurrence in lung cancer patients. We have identified a promising new therapeutic target for lung cancer. This target has been investigated in breast cancer but not in lung cancer where our preliminary data clearly indicates a much stronger indication. Interestingly, a new drug acting on this target is currently being tested in clinical trials for breast cancer. Our goal is to demonstrate using pre-clinical models that this drug is effective for treatment of lung cancer. Should our results prove to be promising, these data will set the stage for early translation to a clinical trial for lung cancer.
Competitiondate
201911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Fiore, Amanda
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~